Agenus Inc. (NASDAQ: AGEN) announced it has triggered the first $20 million contingent payment under its strategic collaboration with Zydus Lifesciences Ltd., according to a company statement.

The payment was activated by work orders for chemistry, manufacturing and controls activities related to botensilimab and balstilimab, the company's lead drug candidates. These activities will enable Zydus to begin commercial supply preparation and support regulatory requirements for biologics license application and marketing authorization application readiness.

The manufacturing work aims to build inventory for clinical development programs, authorized early access pathways, and potential global commercialization. This represents the first operational milestone between Agenus and Zylidac Bio LLC, Zydus Life Sciences' U.S.-based biologics manufacturing subsidiary.

"This milestone reflects our commitment to progressing BOT and BAL to regulatory approval readiness, and to support our ongoing clinical development and paid compassionate access program needs," said Garo H. Armen, chairman and chief executive officer of Agenus.

The collaboration agreement allows for up to $50 million in contingent payments triggered by production orders for the two drug candidates. Agenus stated it currently maintains sufficient clinical-grade drug product inventory to support its ongoing Phase 3 BATTMAN trial, the French access program, and named patient programs in select countries.

The strategic collaboration was announced in June 2025 and closed in January 2026, providing Agenus with long-term U.S.-based biologics manufacturing capacity. The structure allows the company to execute manufacturing work without additional capital expenditures affecting its cash position.

Botensilimab and balstilimab are being developed as combination immunotherapy treatments, with approximately 1,200 patients treated in phase 1 and phase 2 clinical trials to date.